



MEDICAGO RECEIVES 2009 GENESIS INNOVATION AWARD

Quebec City, Quebec— May 15, 2009 — Medicago Inc. (TSX-V: MDG), a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced it received the 2009 Genesis “Innovation” award at gala presented by BIOQuebec on May 14, 2009, in Montreal, Quebec. The Genesis Awards recognize outstanding achievements by companies that play a key role in the growth of Quebec’s biotech, health technology and life sciences industries.

“We are pleased to have received yet another industry award which highlights our innovation behind the utilization of plants and VLPs for the production of vaccines,” said Andy Sheldon, President and CEO of Medicago. “As we transition to a clinical company this year, we are proud that our mission to develop highly effective vaccines, rapidly and cost effectively, has been recognised through this award.”

About Medicago

Medicago is committed to provide highly effective and affordable vaccines based on proprietary Virus-Like Particle (VLP) and manufacturing technologies. Medicago is developing VLP vaccines to protect against H5N1 pandemic influenza, using a transient expression system which produces recombinant vaccine antigens in non-transgenic plants. This technology has potential to offer advantages of speed and cost over competitive technologies. It could deliver a vaccine for testing in about a month after the identification and reception of genetic sequences from a pandemic strain. This production time frame has the potential to allow vaccination of the population before the first wave of a pandemic strikes and to supply large volumes of vaccine antigens to the world market. Additional information about Medicago is available at www.medicago.com.

Forward Looking Statements

This press release contains forward-looking statements which reflect Medicago's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. Medicago disclaims any obligation to update these forward-looking statements.

- 30 -

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

Contact:

Medicago, Inc.
Andy Sheldon
President and CEO
(418) 658-9393

Medicago Inc.
Arianna Vanin
Director, Investor Relations
(514) 796-3993